key: cord-0905424-evux92s4
authors: Demmer, Ryan T.; Baumgartner, Brett; Wiggen, Talia D.; Ulrich, Angela K.; Strickland, Ali J.; Naumchik, Brianna M.; Bohn, Bruno; Walsh, Sara; Smith, Stephen; Kline, Susan; Stovitz, Steve D.; Yendell, Stephanie; Beebe, Timothy J.; Hedberg, Craig
title: Identification of Natural SARS-CoV-2 Infection in Seroprevalence Studies Among Vaccinated Populations
date: 2022-02-14
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2022.02.002
sha: b31eea236d966df9441601fd21ff5af0abd7c501
doc_id: 905424
cord_uid: evux92s4

Most SARS-CoV-2 antibody assays cannot distinguish between antibodies which developed after natural infection from those which developed after vaccination. We assessed the accuracy of a nucleocapsid-containing assay in identifying natural infection among vaccinated individuals. A longitudinal cohort comprised of healthcare workers in the Minneapolis/St. Paul area was enrolled. Two rounds of seroprevalence studies separated by one month were conducted from 11/2020–1/2021 among n=81 participants. Capillary blood from rounds 1 and 2 was tested for IgG antibodies against spike proteins via ELISA (spike-only assay). During round 2, IgGs reactive to SARS-CoV-2 nucleocapsid protein (nucleocapsid-containing assay) were assessed. Vaccination status at round 2 was determined via self-report. Area under the curve (AUC) was computed to determine the discriminatory ability of the nucleocapsid-containing assay for identification of recent infection. Participants had a mean age of 40 (range=23-66) years, 83% were female. Round 1 seroprevalence was 9.5%. Prior to round 2 testing, 46% reported vaccination. Among those not recently infected, when comparing vaccinated vs. unvaccinated individuals, elevated levels of spike 1 (p<0.001) and spike 2 (p=0.01) were observed while nucleocapsid levels were not statistically significantly different (p=0.90). Among all participants, nucleocapsid response predicted recent infection with an AUC(95%CI) of 0.93(0.88,0.99). Among individuals vaccinated >10 days prior to antibody testing, the specificity of the nucleocapsid-containing assay was 92% and while the specificity of the spike-only assay was 0%. An IgG assay identifying reactivity to nucleocapsid protein is an accurate predictor of natural infection among a partially vaccinated population while a spike-only assay performed poorly.

enrolled. Two rounds of seroprevalence studies separated by one month were conducted from 11/2020-1/2021 among n=81 participants. Capillary blood from rounds 1 and 2 was tested for IgG antibodies against spike proteins via ELISA (spike-only assay). During round 2, IgGs reactive to SARS-CoV-2 nucleocapsid protein (nucleocapsid-containing assay) were assessed.

Vaccination status at round 2 was determined via self-report. Area under the curve (AUC) was computed to determine the discriminatory ability of the nucleocapsid-containing assay for identification of recent infection. Participants had a mean age of 40 (range=23-66) years, 83% were female. Round 1 seroprevalence was 9.5%. Prior to round 2 testing, 46% reported vaccination. Among those not recently infected, when comparing vaccinated vs. unvaccinated individuals, elevated levels of spike 1 (p<0.001) and spike 2 (p=0.01) were observed while nucleocapsid levels were not statistically significantly different (p=0.90). Among all participants, nucleocapsid response predicted recent infection with an AUC(95%CI) of 0.93(0.88,0.99).

Among individuals vaccinated >10 days prior to antibody testing, the specificity of the nucleocapsid-containing assay was 92% and while the specificity of the spike-only assay was 0%. An IgG assay identifying reactivity to nucleocapsid protein is an accurate predictor of natural infection among a partially vaccinated population while a spike-only assay performed poorly.

HCW, healthcare worker; S1, SARS-CoV-2 spike subunit S1; S2, SARS-CoV-2 spike subunit S2; ROC, Receiver operator characteristic; AUC, Area under the curve J o u r n a l P r e -p r o o f Identification of SARS-CoV-2 infection via antibody assays is important for monitoring natural infection rates. Currently authorized antibody tests measure antibody reactivity to spike proteins, yet these develop in response to both infection and vaccination 1, 2 . Consequently, ongoing antibody studies will be unable to accurately differentiate prior SARS-CoV-2 infection from vaccination against SARS-CoV-2 in populations with high vaccination coverage.

Current vaccines are not expected to illicit a nucleocapsid response. Consequently, antibody tests that target nucleocapsid proteins can potentially identify prior infection among vaccinated individuals. The purpose of this study was to compare the accuracy of a nucleocapsidcontaining assay vs. a spike protein-only assay in the identification of prior SARS-CoV-2 infection among a sample of healthcare workers (HCW) in the United States.

A sample of healthcare workers located in the Minneapolis/St. Paul, MN, USA, metropolitan area was enrolled 3 and two rounds of seroprevalence studies were conducted from November 2020-January 2021. A subsample of participants (n=81) for whom excess blood was available for testing with both a spike-only assay and a nucleocapsid-containing assay are presently included. The study was approved by the University of Minnesota Institutional Review Board. All participants provided informed consent.

Participants were invited to participate in two rounds of seroprevalence studies (Figure 1 ) and all participants participated in both rounds. Samples were home-collected using Neoteryx Mitra® 10 µl samplers by volumetric absorption of capillary blood from a finger-stick. The first capillary blood specimens were collected between 11/22/2020-12/18/2020 and the second specimens from 12/26/2020-1/08/2021; median time between round 1 and round 2 specimen J o u r n a l P r e -p r o o f collections was 28.5 days (range 12-44 days). All round 1 specimens were collected from participants before vaccinations had become available.

To distinguish antibodies developed after vaccination from those of natural infection two assays were used. The 'spike-only' assay comprises Quansys Q-Plex™ SARS-CoV-2 Human IgG (4-Plex) a qualitative chemiluminescent ELISA that measures Human IgGs reactive to SARS-CoV-2 spike subunit S1 (S1) and spike subunit S2 (S2). A spike-only positive call requires both S1 and S2 antibody levels to exceed assay cutoffs. The second assay measures human IgGs reactive to SARS-CoV-2 nucleocapsid (hereafter, 'nucleocapsid-containing' assay), absent from vaccines, is used to determine natural infection. The assays were developed by Quansys Biosciences, Utah, USA.

Round 1 samples were tested using the spike-only assay and round 2 samples were tested using both the spike-only assay and the nucleocapsid-containing assay.

Assay details are presented in the supplemental materials.

'Recent infection' with SARS-CoV-2 was defined as either a positive result from the round 1 spike-only assay (all round 1 assays were performed prior to vaccination), or a self-report of recent infection. Self-reported vaccinations (vaccinations in the study only contain the spike protein) status (yes/no, dose and date) was assessed from questionnaires. Participants were further classified as having been vaccinated 0-7, 7-10, or >10 days prior to collecting capillary blood during round 2.

Kruskal-Wallis tests compared median IgG response to nucleocapsid protein from the nucleocapsid-containing assay at round 2, by vaccination and infection status. Receiver operator characteristic (ROC) curves were constructed and area under the curve (AUC) was computed to determine the discriminatory ability of round 2 IgG reactivity to nucleocapsid for identification of infection. The optimal nucleocapsid cut-point was defined using Youden's value. 4 The accuracy of identifying infection from Youden's optimal nucleocapsid level was then compared to the accuracy of the spike-only assay using round 2 samples.

The accuracy was also estimated for the nucleocapsid-containing assay using the cut-point defined by Youden's value (described above) in comparison to concurrent round 2 results from the spike-only assay among unvaccinated individuals. In this analysis, infection was defined by results from the concurrent round 2 spike-only assay. These results were then compared against results from the round 2 nucleocapsid-containing assay.

The mean age of participants was 40 (range=23-66) years, 83% were female, 95% white, 2.5% Hispanic and 2.5% Asian. Comorbidities included asthma (14%) coronary artery disease (1%), T2 diabetes (5%) and 2.5% reported being immunocompromised. No participants were vaccinated prior to round 1 testing, while 46% of participants reported vaccination prior to the round 2 testing. Among those vaccinated prior to round 2, the mean time between vaccination and antibody testing was 9 days (range=1 to 34). Round one seroprevalence (via the spike-only assay) was 9.5%.

Median values of S1, S2, and nucleocapsid were all statistically significantly elevated among infected vs. uninfected participants (all p-values <0.0001, Figure 2) . Among individuals who were not infected, elevated levels of S1 (p=0.0005) and S2 (p=0.01) were observed among Among unvaccinated individuals, sensitivities for the spike-only and nucleocapsid-containing assays were 95% and 85% respectively (Table) . Among vaccinated individuals both assays had 100% sensitivity. Among unvaccinated individuals the specificity of the spike-only assay was 86% while among individuals vaccinated >10 days before round 2 testing specificity decreased to 0%. In contrast, the specificity of the nucleocapsid assay increases from 86% to 90% among unvaccinated vs. vaccinated individuals. Regarding participants with apparent false positive findings for the round 2 nucleocapsid-containing assay (i.e., positive result for the nucleocapsidcontaining assay during round 2 and a negative result from the spike-only assay at round 1), the median time between rounds 1 and 2 testing was 33.5 days raising the potential that these individuals were truly infected in the interim.

The supplemental Table presents assay results among unvaccinated individuals for the nucleocapsid-containing assay compared to the gold standard spike-only assay test results from the same blood collection time at round 2; this minimizes the potential for false positive findings.

Sensitivity and specificity were 90% and 100% and, as expected, the specificity improves from 86% to 100%, due to fewer false positive findings.

We evaluated the ability of an IgG antibody assay that assesses reactivity to the nucleocapsid protein to identify previous SARS-CoV-2 infection among a population of HCW, with and without infection, and before and after vaccination. This is the first investigation of this nature to our knowledge. We found that in the context of vaccination, nucleocapsid response is highly predictive of infection. Among vaccinated individuals, the nucleocapsid assay had a substantially higher specificity, and positive predictive value, compared to the spike-only assay.

Results in the table are limited because infection was determined using an antibody test conducted approximately one month before round two testing, and it is possible that participants appearing as a false-positive in the Table, were truly infected between round one and round two and developed an antibody response. Therefore, our findings underestimate specificity for the nucleocapsid-containing assay. Our results are also not generalizable to the general population.

There is likely high value in using nucleocapsid assays for public health surveillance efforts as SARS-CoV-2 infection will likely become endemic and ongoing surveillance studies will be necessary. This is particularly relevant against the backdrop of vaccination where assays targeting the spike protein cannot distinguish natural infection from vaccination. From a clinical perspective, there is potential utility in antibody assays for detecting undiagnosed SARS-CoV-2 infection and assessing post-covid conditions such as multi-inflammatory syndrome in children. 

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

SARS-CoV-2 Screening Among Symptom-Free Healthcare Workers

Index for rating diagnostic tests

An IgG assay identifying reactivity to nucleocapsid protein was an accurate predictor of recent infection among a population of vaccinated HCW. These findings suggest that in the era of SARS-CoV-2 vaccination, seroprevalence studies monitoring natural infection will require assays that capture reactivity to the nucleocapsid protein.J o u r n a l P r e -p r o o f